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Abstract
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation
in clinical trials (phases I to III) to treat Parkinson’s disease, and they will probably soon reach the
market. The usefulness of these antagonists has been deduced from studies demonstrating
functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia. At
present it is believed that A2AR antagonists can be used in combination with the dopamine
precursor L-DOPA to minimize the motor symptoms of Parkinson’s patients. However, a
considerable body of data indicates that in addition to ameliorating motor symptoms, adenosine
A2AR antagonists may also prevent neurodegeneration. Despite these promising indications, one
further issue must be considered in order to develop fully optimized anti-parkinsonian drug
therapy, namely the existence of receptor (hetero)dimers/oligomers of G protein-coupled
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receptors, a topic currently the focus of intense debate within the scientific community. Dopamine
D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine
receptors. Thus, the development of heteromer-specific A2A receptor antagonists represents a
promising strategy for the identification of more selective and safer drugs.
1. Introduction
Adenosine receptors (AR) are members of the G protein-coupled receptor superfamily that
have long been considered potential targets for the treatment of a variety of diseases,
although to date adenosine (Adenocard® or Adenoscan®) is the only commercially
available therapeutic drug acting on AR. Adenocard® is used clinically to revert paroxysmal
supraventricular tachycardia, while Adenoscan® is also used for cardiac imaging due to its
vasodilatory effects mediated by A2A receptors in blood vessels. Recently, the A2A-selective
agonist regadenoson (Lexiscan®) was approved for the same indication. Despite the poor
selection of available compounds, it is still believed that drugs acting on adenosine receptors
will be therapeutically useful. Indeed, five clinical trials are currently underway (phases I to
III) to analyze the therapeutic potential of adenosine A2A receptor (A2AR) antagonists in the
treatment of Parkinson’s disease (PD). Novel adenosine antagonists may thus soon reach the
market. The potential of these antagonists has been deduced from considerable investigation
of the functional interactions between dopamine and adenosine receptors in the basal
ganglia. The use of A2AR antagonists in Parkinson’s disease (PD) is based on solid
preclinical data showing that adenosinergic neuromodulation antagonizes dopaminergic
neurotransmission in aspects relevant to motor control. Adenosine receptor antagonist-based
therapy was initially founded on the hypothesis that preventing such antagonism could be
useful in situations of dopamine deficit, such as occurs in Parkinson’s disease. Notable
efforts in medicinal chemistry have sought to develop A2AR antagonists. While the first
approaches focused on xanthine derivatives, the current portfolio also includes highly
promising non-xanthine drugs.
The use of A2AR antagonists in PD is not exclusively dependent on the outcome of the
ongoing clinical trials with structurally distinct molecules. This is due to a shift in emphasis
from simply improving the motor symptoms of the patients to developing strategies to
prevent disease progression. Given the established efficacy of L-DOPA, and for ethical
reasons, the main approach currently used in clinical trials involves the co-administration of
A2AR antagonists with L-DOPA. The proposed advantage of this strategy is a reduction in
the required dose of L-DOPA, with concomitant reductions in the associated side effects,
consisting mainly of dyskinesias and progressive cognitive impairment. Preclinical findings
also indicated potential neuroprotective effects of A2AR antagonists, an aspect highly
relevant to PD treatment. Thus, in addition to improving motor symptoms when
administered in combination with L-DOPA, A2AR antagonists may also exhibit true disease-
modifying activity, delaying the progression of disease. Whether all A2AR antagonists being
currently assayed in clinical trials are equally effective as co-adjuvants remains to be
determined. However, the development of A2AR antagonists for the treatment basal ganglia
disorders should focus on optimizing both their effects against acute symptoms and their
neuroprotective activity.
An additional and important consideration for the development of A2AR antagonists
concerns the novel pharmacological effects derived from G protein-coupled receptor
heteromerization. The existence of receptor heteromers has had a strong impact on the field
of G protein-coupled receptors, raising important questions as to whether the real therapeutic
targets are receptor monomers, homodimers or heteromers. A2AR and dopamine D2
receptors (D2R) were among the first G protein-coupled receptor heteromers identified, and
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have been detected in both transfected cells and brain striatal tissue (Soriano et al., 2009).
Since receptor pharmacology is modified by heteromerization, the screening of given
receptors in different heteromeric contexts should be incorporated into future drug discovery
programmes. Promising results have been obtained relating to A2AR heteromers (Orrú et al.,
2011), which are implicated in Parkinson’s and Huntington’s diseases (HD), among others.
As structurally distinct A2AR antagonists may exert differential effects on distinct A2AR-
containing heteromers, different A2AR antagonists may be useful for the treatment of
specific neurological disorders, depending on the heteromer preferentially targeted by the
drug. In this review, we aim to address all these past-, present- and future aspects of the
A2ARs and their antagonists.
2. Normal and abnormal basal ganglia function
PD is a basal ganglia-associated disorder that affects 1-2% of individuals over 60 years of
age. The main symptoms of the disease are motor-related, including reduced spontaneous
movement, akinesia (lack of movement), bradykinesia (slowness of movements), rigidity
(due to increased muscular tone), as well as the characteristic resting tremor. The
introduction of the dopamine precursor L-DOPA in the late 1960’s, later followed by a
number of dopamine agonists, has revolutionized the clinical management of PD (at least
within a period of 5-7 years after the first diagnosis, often referred to as the
“pharmacological honeymoon”). These therapeutic tools have proven efficient in restoring
most of the motor-related deficits characterizing PD. However, even the most effective anti-
parkinsonian drugs only provide symptomatic relief. Furthermore, as the disease continues
to progress, troublesome side effects generally appear several years after initiation of
pharmacological treatment, including motor fluctuations (on-off phenomena) and L-DOPA-
induced dyskinesias. In parallel with the appearance of long-term motor disturbances,
patients begin to develop non-motor problems, resulting in a marked decline in quality of
life. At this stage of disease progression, symptoms like mild cognitive impairment
(including dementia in later disease stages), difficulties swallowing and speaking, autonomic
dysfunction, gait disturbances and loss of balance (including frequent falls), represent the
major causes of disability for PD patients. At present, it seems clear that PD cannot solely be
attributed to nigrostriatal dopaminergic deficits. As such the involvement of non-
dopaminergic systems, particularly in relation to the appearance of non-motor symptoms,
needs to be better defined. In this scenario, current strategies aim to either: (i) slow down the
natural progression of PD through disease-modifying therapies, or (ii) better manage the
side-effects that appear after long-term treatment with L-DOPA, particularly ‘on-off’
phenomena and abnormal involuntary movements (i.e.: L-DOPA-induced dyskinesia).
The basal ganglia are a group of subcortical nuclei involved in the planning and initiation of
movement, and are anatomically and functionally organized into parallel circuits that
process different types of information. All basal ganglia-related nuclei are connected
through well-established neurochemical circuits. When considering the activity of these
ganglia, one should bear in mind that after release, the effects of neurotransmitters
ultimately depend on the pre- and post-synaptic localization of a number of receptors, as
well as on the relationships established with other inputs received by a given neuron.
Briefly, the basal ganglia nuclei are divided into: (i) input nuclei that receive information
from the cortex and thalamus, consisting of the caudate, putamen and accumbens nuclei; (ii)
output nuclei that send information from the basal ganglia to the thalamus, comprised of the
internal division of the globus pallidus (GPi) and the substantia nigra pars reticulata (SNr);
and (iii) intrinsic nuclei, composed of the external division of the globus pallidus (GPe), the
subthalamic nucleus (STN) and the substantia nigra pars compacta (SNc). In addition to
these input, output and intrinsic nuclei, several other nuclei are tightly linked to the basal
ganglia system, including the tegmental pedunculopontine nucleus (PPN), the caudal
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intralaminar nuclei (CM-Pf complex), and to some extent, the deep cerebellar nuclei that
also fulfil motor-related functions.
The current model of basal ganglia function and dysfunction (Albin et al., 1989; DeLong,
1990) was postulated in the late 1980’s. This proposes that under tonic dopaminergic
conditions, the striatum (known as the caudate-putamen) integrates cortical and thalamic
information that then reaches the output nuclei, finally arriving to the cerebral cortex via a
thalamic relay. There are two main ways by which striatal information can reach the basal
ganglia output nuclei: firstly, via a monosynaptic projection called the “direct pathway” that
originates in striatal medium-sized spiny neurons (MSNs) expressing dopamine type 1
receptor (D1R) and ends in GPi/SNr nuclei; secondly, through a multisynaptic circuit called
the “indirect pathway”, which begins in striatal MSNs expressing type 2 dopamine receptors
(D2R) that project to the GPe. From the GPe, this latter pathway reaches the output nuclei
after establishing a synaptic relay in the STN nucleus. One of the cornerstones of this model
is the so-called “dual effect” of dopamine at the striatal level, based on the complementary
expression of D1 and D2 receptors by striatal MSNs that project through the direct and the
indirect pathways, respectively. Accordingly, dopamine exerts D1-mediated excitation of
striatal MSNs projecting to GPi/SNr targets, and D2-mediated inhibition of striatal MSNs
innervating the GPe nucleus. Thus, dopamine exerts a dichotomous effect at the striatal level
depending on the type of dopaminergic receptor (D1R or D2R) located post-synaptically in
striatofugal MSNs. Based on this dichotomous effect of dopamine acting on D1R and D2R,
activation of the direct pathway is proposed to facilitate movement, whereas activation of
the indirect pathway is thought to result in movement inhibition. Although anatomical and
functional evidence has challenged this hypothesis (Kawaguchi et al., 1990; Surmeier et al.,
2005; Gatev et al., 2006), it has been recently validated through the use of optogenetic
techniques (Kravitz et al., 2010).
Following dopaminergic denervation, the aforementioned model predicts that the reduced
activation of dopaminergic receptors will decrease the excitation of the D1R-containing
striatofugal neurons of the direct pathway, along with a concomitant disinhibition of D2R-
containing striatal neurons of the indirect pathway. This sequence of events is proposed to
provoke exacerbated GABAergic flux from basal ganglia output neurons, ultimately leading
to excessive inhibition of thalamocortical projections (Crossmann, 1987; Albin et al., 1989;
DeLong, 1990; Obeso et al., 1997). The reverse of this phenomenon is predicted to account
for the dyskinetic state associated with continuous L-DOPA treatment. This induces a
number of downstream changes in basal ganglia circuits, ultimately resulting in hypoactivity
of the basal ganglia output, reducing the inhibition of thalamocortical neurons and leading to
excessive activation of cortical motor areas. This view is strongly supported by previous
studies (Filion et al., 1991; Lozano et al., 2000). In summary, although the current basal
ganglia model served as a good starting point, it is important to stress that basal ganglia
organization is far more elaborate than assumed in this model (reviewed in Obeso et al.,
2000a; Bar-Gad and Bergman, 2001). Indeed, a number of anatomical, electrophysiological
and clinical findings are poorly explained by the current model (Obeso et al., 1997, 2000b;
Wichmann and DeLong, 2000; Nambu, 2008). Many of the inherent limitations of this
model were imposed by the manner in which it was originally conceived, which was
somewhat biased by the preponderance of anatomical and neurochemical data available at
the time. The basal ganglia is thus a much more sophisticated and dynamic network than
that reflected in the basal ganglia model. In addition to new insights into the function of the
basal ganglia at the systems level, recent findings detailing neurotransmission throughout
basal ganglia networks should be taken into consideration for a more complete
understanding of its organization and activity. This is particularly relevant to the role played
by G protein-coupled receptor heteromers in the modulation of striatal neurotransmission, in
Armentero et al. Page 4













normal conditions, under circumstances of dopaminergic depletion and in the dyskinetic
state associated with continuous administration of L-DOPA and/or dopamine agonists.
3. The role of A2A receptors (A2ARs) and A2AR heteromers in the modulation
of striatal neurotransmission
The A2ARs are highly expressed in the basal ganglia and depend on Gs and other interacting
proteins for correct transduction of their signals (Burgueño et al., 2003). The striatum is the
anatomical region in mammals that most strongly expresses A2ARs, which are thought to
fulfil an important role in the regulation of dopaminergic transmission in the basal ganglia
(see Morelli et al., 2009). For instance, A2ARs co-localize postsynaptically with D2Rs in
GABAergic striatopallidal enkephalinergic MSNs. Stimulation of these postsynaptic A2AR
counteracts the inhibitory modulation of NMDA receptor activity mediated by D2Rs, which
includes regulating Ca2+ influx, transition to the firing “up” state and modulation of
neuronal firing in the “up” state (Azdad et al., 2009; Higley and Sabatini, 2010). This
interaction appears to be responsible for most of the locomotor depression and activation
provoked by A2AR agonists and antagonists, respectively (Ferré et al., 2008). Adenosine
A2AR-mediated activity is usually antagonistic to that mediated by striatal D2R in MSNs.
Indeed, functional antagonism between A2A and D2 receptors was recently reported in
striatal cholinergic interneurons (Tozzi et al., 2011). Overall, adenosine-dopamine
antagonism underlies the potential therapeutic benefits of A2AR-selective antagonists in PD.
The well known regulation of motor control mediated by A2ARs under conditions of
dopamine depletion is sufficiently solid to merit the clinical trials currently underway (see
section 7), which aim to demonstrate the therapeutic efficacy of A2AR antagonists in PD.
The existence of A2AR-containing heteromers was first reported at the beginning of the 21st
century (Hillion et al., 2002; Fuxe et al., 2003; Canals et al., 2003; Torvinen et al., 2005).
Since then, accumulating evidence suggests that they may be the real targets of therapeutic
agents used to combat basal ganglia disorders. Receptor heteromers are the focus of intense
research since through heteromerization, receptors become unique functional entities with
different properties from those of each of the receptors involved (Ferré et al., 2009). Thus
A2AR in A2AR-containing heteromers are different therapeutic targets to A2ARs that do not
form heteromers. The allosteric interaction between different receptors in a given heteromer,
e.g., A2AR and D2R in the A2AR-D2R heteromer, may modify the pharmacological
parameters of A2AR or D2R-selective radioligands. In fact, as indicated in section 8.1, a
given A2AR-selective antagonist may display quite different affinities for the “same” A2AR
in different heteromeric contexts. When these allosteric changes are measurable, they may
be considered as a biochemical fingerprint of the heteromer. Identification of biochemical
fingerprints is one of the few procedures available for the detection of heteromers in native
tissues. Using this approach and also by the use of bivalent ligands, A2AR-D2R heteromers
have been detected in brain striatum (Soriano et al., 2009). Moreover, the A2AR-D2R
heteromer has been reported in animal models of PD (data in preparation). Taken together
these findings suggest that dopamine-based therapies for PD (such as L-DOPA) may target
D2R-containing heteromers, while the A2AR antagonists proposed for the treatment of PD
may target A2AR-containing heteromers (reviewed in Franco, 2009 and Casadó et al., 2009).
When attempting to define the physiological significance of the diverse receptor heteromers,
it should be noted that the composition of A2AR-containing presynaptic and postsynaptic
heteromers differs. Postsynaptically, A2AR may not only form heteromers with D2R but also
with cannabinoid CB1 receptors (CB1R). The apparent need for A2AR activation to mediate
the motor-depressant effects of endocannabinoids, which occurs tonically in the presence of
significant levels of extracellular adenosine, appears to be dependent on the existence of
A2AR-CB1R heteromers. This “property” of the CB1R-A2AR heteromer (i.e.: the
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dependence on A2AR activation for CB1R engagement, Carriba et al., 2007), predicts that
A2AR antagonists produce effects similar to CB1R antagonists. Indeed, motor depression
induced by the bilateral striatal infusion of a CB1R agonist in rats is completely counteracted
by systemic administration of either CB1R or A2AR antagonists (Carriba et al., 2007).
Similarly, genetic inactivation of A2AR in mice significantly decreases the cataleptic and
rewarding effects of systemically administered CB1R agonists in a conditioned place
preference paradigm (Andersson et al., 2005; Soria et al., 2006). The existence of
postsynaptic CB1R heteromers provides new indications regarding the potential mechanisms
underlying the endocannabinoid-mediated control of striatal function, as these heteromers
cannot just be considered as retrograde effectors that inhibit neurotransmitter release.
Given the colocalization of CB1, A2A and D2 receptors in striatal neurons and the reported
interplay between A2AR and CB1R, A2AR and D2R, and CB1R and D2R (Hillion et al.,
2002; Tebano et al., 2009; Navarro et al., 2009; Ferré et al., 2010), the existence of striatal
heterotrimers is a clear possibility. It is important to consider that at the structural level,
based on the characterization of the trimer in a heterologous system, a trimer’s function is
determined by its quaternary structure. Indeed, the structural alterations produced in mutant
receptors result in a distinct signalling fingerprint in the trimer. Remarkably, the cross-talk
derived from the co-activation of A2AR and D2R depends on a correct trimer structure,
which requires the presence of the 3 receptors. Indeed, this CB1R-dependent adenosine-
dopamine cross-talk may be considered the fingerprint of the heteromer. The existence of
A2AR-CB1R-D2R heteromers in the striatum is based on the detection of the trimer
fingerprint in slices from wild type but not CB1R KO animals (for details, see Carriba et al.,
2008 and Navarro et al., 2010). Further studies are required to determine the exact role of
A2AR-CB1R-D2R heteromers in striatal function, particularly in states of dopamine
depletion.
Striatal A2ARs are localized both pre and postsynaptically in glutamatergic terminals, where
they heteromerize with A1 receptors (A1Rs) and fine-tune glutamate release (Ciruela et al.,
2006; Quiroz et al., 2009). These A1R-A2AR heteromers appear to work as concentration-
dependent switches (Ferré et al., 2007), with adenosine acting primarily at A1Rs at low
concentrations but at both A1Rs and A2ARs at higher concentrations. Activation of A1R in
the A1R-A2AR heteromer inhibits glutamate release, while the additional activation of the
A2AR produces the opposite effect, acting through a mechanism that seems to involve
allosteric modulation of the receptor heteromer and interactions at the G protein level
(Ciruela et al., 2006, Ferré et al., 2007). Interestingly, presynaptic A2ARs are preferentially
localized in glutamatergic terminals of corticostriatal afferents to the dynorphinergic MSNs
(Quarta et al., 2004; Quiroz et al., 2009). Apart from morphological evidence provided by
immunohistochemistry and electron microscopy, patch-clamp experiments in
enkephalinergic and dynorphinergic MSNs have functionally demonstrated the segregation
of striatal presynaptic A2ARs. Thus, an A2AR agonist and an A2AR antagonist increase and
decrease, respectively, the amplitude of excitatory post-synaptic currents induced by the
intrastriatal stimulation of glutamatergic afferents measured in enkephalinergic, but not
dynorphinergic MSNs. Indeed, a mean-variance analysis indicates a presynaptic locus for
the effect mediated by A2AR (Quiroz et al., 2009). These findings suggest a selective A2AR-
mediated modulation of glutamate release to dynorphinergic MSNs, a scenario which
contrasts with the recently proposed role of post-synaptic A2ARs in the modulation of
glutamate release to enkephalinergic MSNs (Lerner et al., 2010).
The data presented in this section indicate that heteromers containing A2AR must be
considered when attempting to understand the effects of selective A2AR agonists and
antagonists, and when developing compounds to compensate for basal ganglia dysfunction.
Two main types of A2AR-containing heteromers exist, namely pre- and postsynaptic. The
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prototypic presynaptic striatal receptor is the A1R-A2AR found in glutamatergic terminals.
Post-synaptic striatal heteromers containing A2AR in the spines of GABAergic
enkephalinergic neurons are formed with D2R and/or CB1R. Targeting pre- versus
postsynaptic A2AR, or vice versa, may represent a useful approach to differentially combat
disorders affecting the basal ganglia.
4. OVERVIEW OF IMPORTANT A2AR ANTAGONISTS
Several review articles on adenosine receptor ligands in general (Müller & Jacobson, 2011a;
Müller & Jacobson, 2011b; Fredholm et al., 2011) and A2AR antagonists in particular
(Müller & Ferré, 2010; Clementina & Giuseppe, 2010; Shah & Hodgson, 2010; Cristalli et
al., 2009) have appeared recently. The first adenosine receptor antagonists described in the
literature were the plant alkaloids caffeine (1) and theophylline (2), which are characterized
by their core xanthine structure (Figure 1). These compounds are non-selective, relatively
weak antagonists with Ki values in the micromolar concentration range for the four human
receptor subtypes (see Table 1) and are approximately equally potent at rat A1, A2A and A2B
receptors, though do not act at the rat A3 receptor subtype.
5. Rationale for the screening of adenosine A2AR antagonists to prevent
neurodegeneration in Parkinson’s disease
5.1. Neuroprotection and Parkinson’s disease - a general outlook
Replenishing the depleted dopamine stores with L-DOPA, its immediate precursor, thus
mimicking dopamine-mediated neurotransmission, remains the basis of current PD
treatment. Although this replacement therapy offers immediate and effective symptomatic
relief, especially in the early stages of the disease, it does not have any influence on the
underlying neurodegenerative processes. As a consequence, neuronal cell death progresses
over time and is paralleled by a gradual loss of drug efficacy. Thus, steady adaptation is
necessary to maintain adequate symptomatic relief, mainly by increasing the doses of
dopaminergic drugs, thereby favouring the emergence of side effects, such as dyskinesia and
psychiatric disturbances. The discovery of new drugs, or the combined use of known
compounds that not only alleviate motor symptoms but that also delay or even halt the loss
of dopaminergic neurons, are fundamental issues in generating alternative therapeutic
strategies for PD.
The search for neuroprotective therapies in PD has continued for more than a quarter of a
century, involving an impressive number of patients thus far (Voss & Ravina, 2008). Some
encouraging results have been obtained using rasagiline, a potent MAO-B inhibitor (Olanow
et al., 2008; Olanow et al., 2009; Weinreb et al., 2010), which produces disease-modifying
effects in PD patients in early treatment stages. Nevertheless, to date no drug demonstrating
neuroprotective effects has been unequivocally approved for use in humans. A major
drawback in the development of a neuroprotective therapy is the multifactorial nature of PD.
The primary causes of the degenerative process underlying the disease remain unclear.
Aside from several gene mutations that have been shown to cause familiar PD (Nuytemans
et al., 2010), extensive studies using experimental models of PD, as well as large post-
mortem studies have identified the presence of numerous cellular and molecular defects. In
particular, oxidative stress and excitotoxic mechanisms, mitochondrial and ubiquitin/
proteasomal system (UPS) dysfunction, increased MAO (MAO-A and MAO-B) activity, as
well as significant neuroinflammatory processes have all been associated with PD (Cookson
& Bandmann, 2010). Any of these alterations could, in principle, represent a potential
therapeutic target and many have indeed been singularly targeted (Schapira, 2009). It has
become evident over the years however, that pathogenetic pathways do not contribute to
disease severity in a linear fashion but rather are highly interconnected and act in parallel.
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Therefore, processes leading to nigral cell death are likely to represent the reciprocal
cumulative interaction of factors that have little effect on their own. Similarly, mechanisms
that sustain ongoing cell loss might differ from initial triggers and are likely to change as
dopaminergic neurodegeneration progresses. This strongly suggests that drugs with a single
target will be unable to compensate for, or correct, complex alterations. To restore altered
activities and potentially slow down disease progression, any therapeutic strategy for PD
will likely have to: i) act on different pathways simultaneously; and ii) adapt and evolve as
the disease progresses. Thus, as the causes of PD are manifold and interconnected, it is clear
that a multilateral approach is needed to effectively treat this complex neurodegenerative
disease, using a combination of molecules acting on different pathways. Alternatively,
different compounds with promiscuous activity could be developed that operate at multiple
targets, providing both symptomatic and neuroprotective benefits.
Antagonists of A2AR have proven highly efficient in restoring motor function in animal
models of PD and, as described below (see section 7), have produced some encouraging
results in clinical trials. Blockade of A2AR may confer neuroprotection against a large
spectrum of brain insults in animal models of ischemia, epilepsy, PD, HD and Alzheimer’s
disease (AD: Gomes et al., 2010). We will review how A2AR antagonists, aside from their
well-documented effects on the motor symptoms characteristic of PD, can target several
cellular mechanisms implicated in the underlying neurodegenerative process and possibly
confer significant neuroprotection in PD.
5.2. Caffeine, A2AR antagonists and PD – when the past meets the present
In past decades, several large convergent follow-up studies involving more than 150,000
subjects, both male and female, have demonstrated an inverse relationship between the
consumption of coffee and the risk of developing PD (Costa et al., 2010). In particular,
consumption of caffeinated but not decaffeinated coffee was correlated with a reduced risk
of developing the disease (Ascherio et al., 2001; Powers et al., 2008; Ross et al., 2000a;
Ross et al., 2000b; Saaksjarvi et al., 2008), indicating that caffeine, a non selective A1/A2A
receptor antagonist, is directly implicated in neuroprotection. Indeed, a large body of
evidence continues to support the neuroprotective potential of caffeine both in vitro and in
vivo.
In vitro, caffeine (1) can protect rat mesencephalic cells from 6-hydroxydopamine (6-
OHDA) toxicity, increasing cell viability, reducing the number of apoptotic cells and
completely blocking toxin-induced lipid peroxidation (Nobre et al., 2010). Importantly, in
these cell cultures caffeine also reduces the number of activated astrocytes and microglia
induced by the neurotoxin. Caffeine also protects against 1-methyl-4-phenylpyridinium
(MPP+)-induced mitochondrial complex I inhibition in cerebellar granule neurons (Alvira et
al., 2007). Recently, the development of a rapid assay to evaluate neuroprotective agents has
confirmed that caffeine can efficiently reduce toxin-induced PD-related abnormalities in
SH-SY5Y cells (Yong-Kee et al., 2010). Analogously, caffeine prevented apoptotic cell
death and induced phosphorylation of protein kinase B (Akt) in a dose-dependent manner,
suggesting that it exerts a protective effect through activation of the PI3K/Akt pathway
(Nakaso et al., 2008), a pathway known to be altered in PD (Armentero et al., 2010;
Morisette et al., 2010).
In vivo, administration of caffeine in different experimental paradigms (acute vs chronic,
pre- vs. post-treatment) protected against nigrostriatal degeneration in 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice (Chen et al., 2001b; Kalda et al.,
2006; Singh et al., 2009; Xu et al., 2002), a well characterized animal model of PD.
Recently, caffeine has also been shown to attenuate the loss of dopaminergic neurons in
mice treated with a combination of paraquat and maneb (Kachroo et al., 2010), two
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pesticides linked to increased risk of developing PD (Costello et al., 2009). Notably, caffeine
treatment reduced neuronal cell death and glial activation in lipopolysaccharide (LPS)-
treated mice (Brothers et al., 2010), an animal model of dopaminergic degeneration. A
recent exhaustive effort to identify genes involved in the molecular mechanisms of caffeine-
mediated neuroprotection towards MPTP-induced alterations in mice clearly demonstrated
that caffeine can modulate the expression of proteins involved in PD pathogenesis, including
UPS related genes, cytochrome oxidase (subunit VIIc) gene and genes involved in the
regulation of microglial activation (Singh et al., 2010). Interestingly, recent evidence
indicates that caffeine can also counteract alterations to the blood-brain barrier (BBB)
known to occur in neurodegenerative disease, including PD (Chen et al., 2010).
Although caffeine can act on both A1R and A2AR, converging evidence demonstrates that
blockade of A2AR but not A1R contributes to its actions in the brain (Fredholm et al., 1999).
Indeed, the effects of caffeine per se appear to be largely abolished in A2AR knockout mice
(El Yacoubi et al., 2000; Huang et al., 2005). Since the initial discovery of the
neuroprotective potential of caffeine, numerous A2AR antagonists have been developed,
mainly belonging to two chemical classes (see section 4 above; Müller & Ferré, 2010).
Xanthine-based antagonists, such as CSC (6), DMPX (4), and KW-6002 (5), or non-
xanthine-based A2AR antagonists including SCH-58261 (10), all demonstrate a clear
potential to reduce toxin-induced neuronal cell death in rodent models of PD (Carta et al.,
2009; Chen et al., 2001b; Ikeda et al., 2002; Joghataie et al., 2004; Pierri et al., 2005).
Conversely, A1R antagonists such as DPCPX show no such protective effect (Chen et al.,
2001b). Recent evidence has further demonstrated that other methylxanthines that
effectively block A2AR, such as theophylline (2) and paraxanthine (3: Xu et al., 2010), can
also provide neuroprotection in MPTP mice.
The mechanisms by which A2AR antagonists may attenuate the demise of dopaminergic
neurons are still unknown. However, the effects of A2AR antagonists extend beyond those
demonstrated in PD models. A2AR antagonists have been shown to decrease excitotoxic
lesions in the hippocampus and striatum (Jones et al., 1998a, 1998b; Popoli et al., 2008;
Popoli et al., 2002), as well as cerebral and striatal damage associated with ischemia
(Monopoli et al., 1998; Phillis, 1995). In A2AR knockout mice, the volume of infarction
induced by transient occlusion of the middle cerebral artery is significantly reduced by
caffeine (Chen et al., 1999). A2AR antagonists also offer protection in a mouse model of HD
(Chen et al., 2007). These converging findings, along with evidence that genetic deletion of
A2AR in mice almost completely prevents MPTP-induced nigrostriatal degeneration (Chen
et al., 2001a), strongly suggests that caffeine and A2AR antagonists counteract a range of
noxious insults affecting different brain regions. Considering the multifactorial and
progressive nature of PD, antagonists of A2AR that can act at multiple cellular levels may be
good candidates to intervene, slow down or even halt the underlying neurodegenerative
process in this disease.
5.3 A2AR antagonists and glutamate toxicity
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and
it is involved in many essential brain functions, including synaptic plasticity, memory and
learning, and repair. In the basal ganglia, glutamate mediates excitatory transmission at
crucial points and is instrumental in the mechanisms that underlie motor symptoms in PD.
Under specific conditions glutamate exerts excitotoxic effects due to glutamate-triggered
overload of intracellular calcium. Although compensatory mechanisms allow neurons to
deal with contained, self-limited increases in calcium influx, they cannot cope with
protracted noxious stimuli. Excitotoxicity is considered a crucial component of numerous
pathological conditions in the CNS, including PD in which it may contribute to and/or
sustain the inherent neurodegeneration (Blandini, 2010). Reducing glutamate overdrive thus
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represents an important strategy to favour neuroprotection in PD (Blandini et al., 2001;
Piallat et al., 1996).
As mentioned above, A2AR antagonists protect against a wide range of excitotoxic brain
insults, from ischemia to HD. About one third of the A2AR immunoreactivity in the brain is
observed in cortico-striatal glutamatergic terminals, and under both normal and pathological
conditions, adenosine is known to modulate the pre-synaptic release of glutamate via A1R
(inhibition) or A2AR (facilitation). A2AR antagonists can thus reduce glutamate release by
enhancing the inhibitory activity of A1R and therefore may partially exert neuroprotective
effects against excitotoxity by modulating (inhibiting) glutamate release from pre-synaptic
terminals (Chen et al., 2007; Cunha, 2005).
The SNc is vulnerable to small, non-toxic changes of glutamate levels. In PD, hyperactivity
of GABAergic enkephalinergic neurons induced by the release of D2R-mediated tonic
inhibition causes functional alterations of basal ganglia circuits and triggers hyperactivity in
the STN. As well as projecting to the GP and SNr, the STN also targets the SNc (Smith et
al., 1996). Glutamatergic over-stimulation that may initially enhance the activity of
dopaminergic neurons and compensate for their loss, may over time act as a noxious
stimulus, further sustaining neuronal death (Shimo & Wichmann, 2009). A2AR antagonists
may potentially decrease the glutamate-dependent excitation of GABAergic enkephalinergic
neurons through pre- and post-synaptic mechanisms (see above), thereby reducing the STN-
dependent glutamate overstimulation of the SNc, further sustaining their proposed anti-
excitotoxic effect in PD. Recently, effects on A2ARs expressed by astrocytes has emerged as
an additional mechanism by which A2AR antagonists can modulate glutamate release and
consequently, cell death (see below section 5.4.2).
5.4 A2AR antagonists and modulation of neuroinflammatory processes
In the past decade, neuroinflammation has emerged as an important substrate for PD (Hirsch
& Hunot, 2009). Indeed, several epidemiological studies have reported an inverse
correlation between the chronic consumption of non-steroid anti-inflammatory drugs and the
risk of developing PD (Chen et al., 2003). Although inflammatory reactions initially aim to
restore physiological tissue function, chronic stimuli, resulting from overt tissue damage
and/or protein aggregation may result in a persistent inflammatory response, provoking a
feed-forward loop that overwhelms normal mechanisms of control. As such, uncontrolled
inflammation may produce toxic factors that amplify underlying disease states. There is
significant evidence demonstrating that neuroinflammatory processes participate in the
pathophysiology of PD, and gliosis and lymphocyte infiltration have been consistently
reported in the SNc of PD patients (McGeer & McGeer, 1998; McGeer et al., 1988; McGeer
& McGeer, 2002, 2008; McGeer et al., 2001). Neuroinflammation is also associated with
soluble factors - protective or toxic - that are produced and secreted not only by resident
cells in the brain (astrocytes and microglia) but also, by peripheral immune cells that can
traffic to the brain parenchyma (Koistinaho & Koistinaho, 2005; McGeer & McGeer, 2004;
Minghetti, 2005; Perry & Gordon, 1988; Raivich et al., 1999; Tuppo & Arias, 2005).
Similarly, the nigrostriatal neurodegeneration caused by all major neurotoxins used to
reproduce PD features in animal models (6-OHDA, rotenone, MPTP) is invariably
associated with intense glial cell activation (Abbott, 2000; Armentero et al., 2006b; Carta et
al., 2009; Sherer et al., 2003), lymphocyte infiltration (Brochard et al., 2009), and the
production of soluble inflammatory factors (Armentero et al., 2006a; McGeer et al., 2001).
The levels of neuroinflammatory mediators, such as tumor necrosis factor (TNF)-alpha and
interleukin-1, are elevated in the brain of PD patients, and in parkinsonian rodents and non-
human primates (Barcia et al., 2005; Hirsch et al., 1998; Nagatsu & Sawada, 2005).
Importantly, most studies in animal models of PD have demonstrated that neuroprotective
strategies that effectively reduce nigrostriatal degeneration are consistently associated with a
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reduction in neuroinflammatory processes and vice versa, highlighting the fundamental link
between neuroinflammation and neurodegeneration.
Aside from its well documented distribution in basal ganglia nuclei, A2AR is also expressed
by cells associated with the neuroinflammatory process, namely astrocytes (Brambilla et al.,
2003; Fiebich et al., 1996; Lee et al., 2003; Nishizaki et al., 2002; Wittendorp et al., 2004),
microglia (Fiebich et al., 1996; Hasko et al., 2005) and oligodendrocytes (Stevens et al.,
2002). Accumulating evidence indicates that A2AR ligands may modulate
neuroinflammatory responses associated with neurodegeneration. Caffeine significantly
reduces the number of activated hippocampal microglia in aged LPS-treated rats (Brothers et
al., 2010) and pre-treatment of MPTP-mice with A2AR antagonists is associated with weaker
glial activation in both the SNc and striatum (Carta et al., 2009; Ikeda et al., 2002; Pierri et
al., 2005; Pinna et al., 2010; Yu et al., 2008)
Recently, studies using a conditional mouse knockout of forebrain A2AR (fb-A2AR KO
mice: Yu et al., 2008) have emphasised the importance of glial A2AR expression in
nigrostriatal degeneration. These mice do not suffer the well-characterized motor effects
produced by the A2AR antagonist KW-6002. Moreover, fb-A2AR KO mice show the same
susceptibility towards elevated acute MPTP neurotoxicity as their wild type littermates (Yu
et al., 2008), and both nigrostriatal degeneration and glial activation can be reduced by
additional A2AR blockade with KW-6002 (5). Interestingly, the dopaminergic striatal
terminals and nigral neurons of fb-A2AR KO mice exposed to weak chronic MPTP
intoxication suffer little or no damage, though reduced glial activation is evident (Carta et
al., 2009). Importantly, the antagonist doses used to achieve neuroprotection were several
times lower than those required to induce motor effects. Hence, the cellular and molecular
mechanisms involved in A2AR-mediated neuroprotection are likely to be distinct from those
required mediating motor effects, and likely occur through glial cells.
5.4.1 A2AR antagonists and microglial cells—Microglia are among the main resident
immune cells in the brain. Under physiological conditions, microglial cells exhibit what has
been defined as a “surveying” phenotype, characterized by a small soma and long processes.
These cells constantly and randomly scan their surrounding microenvironment, rapidly
reacting to any local disturbances by producing soluble factors that influence nearby neurons
and astrocytes. It is now well established that microglia continuously engage in minor
transient and self-limiting repairs that rapidly resolve such situations and generally go
unnoticed (Hanisch & Kettenmann, 2007). Within minutes of brain damage these cells send
microglial processes to the site of injury, guided by specific local chemoattractants released
from affected tissue (such as ATP or ADP), a response that is dependent on stimulation of
the purine receptor P2Y12 (P2Y12R) expressed by microglia (Davalos et al., 2005).
However, this situation changes under conditions of prolonged chronic brain damage, such
as that observed in neurodegenerative diseases like PD. Following chronic activation,
microglia typically assume an amoeboid morphology with highly retracted processes (Block
et al., 2007; Hanisch & Kettenmann, 2007; Kreutzberg, 1996; Stence et al., 2001). While
this retraction is also driven by ATP, it is characterized by the repulsion from ATP, and
correlates with the down-regulation of P2Y12R and up-regulation of A2AR by the activated
cells (Haynes et al., 2006; Moller et al., 2000; Orr et al., 2009).
The use of transgenic mice that express the enhanced green fluorescent protein (eGFP)
under the control of A2AR promoter has further confirmed that inflammatory stimuli, such
as intracerebral LPS injection, can induce strong up-regulation of A2AR in microglial cells.
Furthermore, inducers of brain inflammation such as TNF-alpha and beta-amyloid can
down- and up-regulate of P2Y12R and A2AR expression, respectively (Orr et al., 2009), a
phenomenon that has also been described in human macrophages and brain tissues from AD
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patients (Angulo et al., 2003). Interestingly, when A2AR is activated in induced microglia
using selective agonists (5’-N-ethylcarboxamide adenosine, NECA, and its C2-substituted
derivative, CGS-21680), withdrawal of the cellular processes is stimulated and the
characteristic highly activated amoeboid phenotype of microglial cells is adopted (Fredholm
et al., 2001; Ongini & Fredholm, 1996). Conversely, when LPS-injected Cx3Crl-eGFP
transgenic mice that specifically express the eGFP protein in microglia (Davalos et al., 2005;
Haynes et al., 2006; Nimmerjahn et al., 2005) are treated with the A2AR antagonist
SCH-58261(10), the repulsion of activated microglial processes from ATP at the inflamed
site is attenuated, and the reversion of microglial cells from a highly activated amoeboid
phenotype towards a less activated phenotype with processes is impaired (Orr et al., 2009).
These results are in agreement with the observation that reduced nigrostriatal degeneration
in MPTP mice treated with the A2AR antagonist KW-6002 (5) is accompanied by a
reduction in neuroinflammation, characterized by a specific decrease in the number of large,
activated amoeboid microglial cells (Yu et al., 2008). These data clearly indicate that A2AR
plays a fundamental role in the stepwise activation of microglia. A2AR antagonists may help
limit the development of a fully activated, amoeboid, noxious microglial phenotype, thereby
breaking a vicious circle in which neurodegeneration and neuroinflammation sustain each
other. Interestingly, it can be inferred that treatment with A2AR antagonists may be “useful”
at later stages of the neuroinflammatory process when advanced microglial activation is
evident.
The functional plasticity of microglial cells is not only evident through changes in
morphology and the expression of cell surface receptors, but also through modified
production and release of soluble factors. Microglia represent a source of neurotoxic factors
that can further drive neuronal damage, and the extreme vulnerability of the SNc to
oxidative stress is likely correlated with a greater microglial density as compared with in
other brain regions (Lawson et al., 1990). Alterations in the levels of soluble modulators
such as nitric oxide (Knott et al., 2000), IL-1beta, IL-6, IFN-gamma, and TNF-alpha have
been detected in the SNc of PD patients (Marchetti & Abbracchio, 2005; McGeer &
McGeer, 2008; Tansey & Goldberg, 2010; Whitton, 2007). Moreover, A2AR stimulation can
enhance nitric oxide release by activated microglia, while blockade of the receptor with the
antagonist ZM-241385 (9) significantly suppresses the release of this noxious molecule
(Saura et al., 2005). Thus, attenuation of nitric oxide production could contribute in part to
the neuroprotective effect afforded by A2AR antagonists. Similarly, ZM-241385 (9) reduced
IL-1beta activation in quinolic acid-treated rats (Stone & Behan, 2007), SCH-58261 (10)
prevented cyclooxygenase (COX)-2 expression by striatal microglial cells (Chen et al.,
2007), and blockade of A2AR with caffeine (1) diminished TNF-alpha release from LPS-
activated monocytes (Chavez-Valdez et al., 2009).
Activation of the mitogen-activated protein kinase (MAPK) p38 signalling cascade causes
cytokine release and has been implicated in PD pathogenesis. Inhibitors of the MAPK p38
pathway thus represent potential therapeutic agents for the treatment of neurodegenerative
diseases (Yasuda et al., 2010). Recently, repeated administration of the selective A2AR
antagonist SCH-58261 (10) was shown to reduce MAPK p38 activation in microglial cells
(Melani et al., 2006). These data suggest that blocking A2AR may impede
neurodegeneration by modulating the release of noxious factors by activated microglia.
5.4.2. Effects of A2AR antagonists on astrocytes—Astrocytes are strategically
localized in close contact with neuronal structures in all regions of the brain. It has now
become evident that astrocytes do not solely endow a structural support to neurons but also
play a fundamental role in maintaining their environment. Astrocytes are considered an
essential part of a neuronal-glial-vascular unit, strictly controlling local blood flow,
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supplying neurons with energy substrates and representing a fundamental homeostatic
element in the brain (Magistretti, 2006; Mulligan & MacVicar, 2004; Zonta et al., 2003).
Like microglia, astrocytes react rapidly to CNS injury and their activation has been reported
consistently in PD patients (McGeer & McGeer, 2008) and in toxin-induced animal models
of the disease (Armentero et al., 2006a; Carta et al., 2009). Nevertheless, the precise
neuroprotective and/or neurotoxic influence of activated astrocytes in PD remains poorly
understood, and appears to rely on the molecules released into and taken up from the
extracellular space. Beneficial effects of astrocytes include the support and sustenance of
correct neural function, derived from the initial release of neurotrophic factors, including
glial-derived neurotrophic factor (GDNF) and nerve growth factor (NGF), as well as of
antioxidant molecules like glutathione. However, protracted astrogliosis may be detrimental
due to the secretion of neurotoxic substances that hinder functional recovery or induce
damage. Astrocytes normally support axonal growth (Privat, 2003), although prolonged
activation can lead to formation of a glial scar at the site of lesion and inhibit axon
regeneration (Rolls et al., 2009). Significant and persistent phenotypic changes, such as
hypertrophy and up-regulation of glial fibrillary acidic protein (GFAP), have been observed
in activated astrocytes. Inflammation per se has been shown to enhance the density of
A2ARs on astrocytes, leading to an increase in proliferation and activation of the cells.
Stimulation of A2AR can induce the secretory activity of the cells (DeLeo & Yezierski,
2001; Fiebich et al., 1996) and further enhance their proliferation and activation (Brambilla
et al., 2003; Bura et al., 2008; Minghetti et al., 2007). Conversely, the A2AR antagonists
DPMX (4), SCH-58261 (10) and KW-6002 (5), have opposite effects (Brambilla et al.,
2003), and A2AR blockade downregulates GFAP immunoreactivity in primary astrocytes
and rodent models of neurodegeneration (Brambilla et al., 2003; Ke et al., 2009; Minghetti
et al., 2007). Consistent with these findings, A2AR knockout mice display limited astroglial
growth (Bura et al., 2008).
The blockade of A2AR in astrocytes appears to reduce noxious astrogliosis and
neurodegeneration. Indeed, astrocytes fulfil an important function by buffering
neurotransmitter activity, which can be modulated through A2AR. There is also evidence
that the A2AR modulates glutamate release and uptake from astrocytes (Cunha, 2005) and is
involved in intracellular calcium release in astrocytes (Doengi et al., 2008). Chronic
neuroinflammation is associated with inhibition of glutamate uptake and enhanced release of
glutamate by astrocytes (Bezzi et al., 2001), a phenomenon further amplified by activated
microglia (Rothwell et al., 1997). Indeed, A2AR agonists can enhance glutamate efflux in
cultured astrocytes while receptor blockade significantly reduces the levels of extracellular
glutamate (Chen & Pedata, 2008; Li et al., 2001; Nishizaki et al., 2002). Thus, A2AR
antagonists could potentially modulate astrogliosis to reduce inflammatory burden in PD and
alleviate the excitotoxicity associated with the incorrect handling of extracellular glutamate
by activated astrocytes.
5.4.3. Effect of A2AR antagonists in the blood-brain-barrier and peripheral
immune system—The blood-brain barrier (BBB) is a fundamental separation between the
CNS and systemic circulation that regulates and protects the brain microenvironment. BBB
integrity favours proper CNS functioning and its alteration leads to changes in neuronal
behaviour and survival (Zlokovic, 2008). The stability of the BBB depends mainly on the
presence of the tight junctions that form between adjacent endothelial cells, which are
tightly regulated at both the protein level and by multiple cell signalling pathways (Abbott &
Revest, 1991; Ishizaki et al., 2003; Stelzner et al., 1989). BBB disruption has been reported
to contribute to PD progression in patients and various animal models of the disease
(Kortekaas et al., 2005; Carvey et al., 2005; Zhao et al., 2007; Stolp & Dziegielewska, 2009;
Weiss et al., 2009). In particular, endothelial alterations in the SNc of PD patients have been
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detected (Faucheux et al., 1999). In addition, disruption of BBB permeability per se can
induce dopaminergic neurodegeneration (Rite et al., 2007), while both neuroinflammation
and oxidative stress compromise BBB permeability.
In MPTP-treated mice, chronic ingestion of caffeine (1) protects against toxin-induced BBB
dysfunction. In these mice, caffeine significantly reduced the disease-related Evan’s blue
and albumin leakage in the striatum, as well as the diminished expression of tight junction
protein, indicative of BBB dysfunction (Chen et al., 2008). The A2AR is also strongly
expressed by brain endothelial cells (Phillis, 1989; Schaddelee et al., 2003) in which
caffeine likely modulates cAMP levels and affects the release of calcium from intracellular
stores (Chen et al., 2010). Interestingly, by acting through A2AR caffeine can also protect
the BBB by modulating lipid and/or cholesterol metabolism (Reiss et al., 2004). Activated
glial cells release pro-inflammatory and neurotoxic factors, including TNF-alpha, reactive
oxygen species and interleukins, all of which alter the BBB (Abbott, 2000). Therefore,
caffeine may also help maintain BBB integrity by modulating other cell types including
astrocytes, microglia and neurons (see above).
If the BBB is disrupted, peripheral immune cells can cross into the brain parenchyma,
further enhancing neuroinflammatory processes, thereby creating a noxious feed-forward
loop. In chimeric mice in which A2AR can be selectively inactivated in bone marrow-
derived cells (Dai et al., 2010), important cellular regulators of inflammation in the CNS
(Yu et al., 2004) attenuate neurological deficits and reduce cell apoptosis in mice following
traumatic brain injury. This protective effect is probably linked to the inhibition of glutamate
and inflammatory cytokine release. Recent work has indicated that peripheral cells,
including lymphocytes, also express detectable levels of A2AR, the expression of which is
augmented in PD patients (Varani et al., 2010). Thus, modulation of BBB permeability and
the circulation of immune cells from the periphery to the brain parenchyma following
modulation of A2ARs may be an important therapeutic intervention in PD.
5.5 A2AR antagonists and MAO inhibition
MAOs (MAO-A and MAO-B) constitute the major catabolic pathway for dopamine in the
striatum and they have been considered an important target for PD treatment. MAO-B is
predominantly expressed by glial cells (Levitt et al., 1982), and its activity increases both
with age and glial activation (Fowler et al., 1997; Youdim & Bakhle, 2006). Inhibition of
MAO-B may slow the depletion of dopamine stores and elevate the levels of both
endogenous dopamine and dopamine produced from exogenously administered L-DOPA
(Finberg et al., 1998). Furthermore, oxidation of dopamine by MAO-B leads to the
generation of H2O2, which can readily react with free iron (II) ions, exacerbating
neurodegeneration. Inhibitors of MAO-B may confer neuroprotection by decreasing
potentially hazardous by-products in the brain (Sagi et al., 2007). Accordingly, rasagiline, a
potent selective inhibitor of MAO-B, exhibits significant neuroprotective activity in various
animal models of PD (Blandini et al., 2004; Sagi et al., 2007) and has demonstrated some
benefits in slowing disease progression in a phase III delayed-start clinical study (Olanow et
al., 2008; Olanow et al., 2009; Weinreb et al., 2010). Reversible inhibition of MAO-B
activity has been reported for several A2AR antagonists (Castagnoli et al., 2003; Chen et al.,
2001; Petzer et al., 2009; Petzer et al., 2003; Pretorius et al., 2008; Vlok et al., 2006),
including very high concentrations of KW 6002 (5: Ki = 28 μM) and CSC (6, Ki = 80.6 nM),
two antagonists that significantly reduce nigrostriatal degeneration in the MPTP mouse
model. These results indicate that the neuroprotective properties of CSC may partly involve
MAO-B inhibition in the brain, in synergy with A2AR antagonism.
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The past two decades have provided substantial information regarding the neuroprotective
potential of caffeine and A2AR antagonists. The selective blockade of A2AR has been shown
to benefit many brain disorders caused by a wide spectrum of insults, though the
mechanisms underlying their neuroprotective potential in PD remain to be established. As
indicated above, accumulated data suggests that this neuroprotective influence may differ
from, and/or be complementary to the well-characterized motor stimulatory effects of these
compounds. Indeed, the mechanisms underlying the neuroprotective role of A2AR against
nigrostriatal degeneration appear to be complex, requiring further study. A2AR may afford
neuroprotection by modulating glutamate release and uptake, thereby reducing the
excitotoxic burden, as well as by diminishing the production of toxic metabolites through
the inhibition of MAO-B. A2AR antagonists may also alter the behaviour of the BBB and the
transit of peripheral immune cells to the damaged brain parenchyma. Importantly, A2AR
antagonists may affect glial activation and limit, or even revert, the development of fully
activated noxious microglia and astrocytes, thereby influencing neurodegeneration and
neuroinflammation. The existence of heteromerization and crosstalk between A2AR and
other G protein-coupled receptors has also been demonstrated, whereby blockade of A2AR
can modulate the activity of companion receptors and further enhance their positive effects
against dopaminergic cell loss.
Although it is well accepted in animal models of PD that A2AR expression increases in
neurons (Rebola et al., 2005) and glia (Yu et al., 2008) under noxious conditions (Cunha,
2005), better definition of the pharmacological properties, localization and disease-related
modifications of A2AR in the human brain is required, both in terms of anatomical
expression and heteromerization. It is evident that the phase of the disease at which an
antagonist is administered is a critical factor in terms of the magnitude of the effect and the
final outcome. Hence, the development of new compounds acting on receptor heteromers
containing A2AR represents an innovative and potentially beneficial therapeutic strategy for
the treatment of PD.
6. Rationale behind the screening of adenosine A2AR antagonists to
improve motor symptoms in animal models and Parkinson’s disease
The use of A2AR agonists has been associated with side effects, with 184 out of 334 patients
(20 out of 170 in the placebo group) reporting adverse effects in the clinical trial
NCT00863707 of regadenoson administered by intravenous bolus injection (0.4 mg/5 ml:
available at http://clinicaltrials.gov), including headache, nausea, chest discomfort, dyspnoea
or dizziness. Nevertheless, A2AR agonists like regadenoson are safe and well tolerated when
applied as pharmacological stress agents for myocardial perfusion imaging, even after heart
transplant (Cavalcante et al., 2011). By contrast, A2AR antagonists are generally quite safe,
as demonstrated in clinical trials with KW-6002 and preladenant (see below) in which
treated patients do not display stable alterations in blood pressure or signs of irritability or
anxiety. Therefore, the phenotype described for A2AR KO mice does not occur in humans
treated with A2AR antagonists. Thus, while A2AR agonists may be suitable for use in acute
controlled (myocardial perfusion imaging) or topical interventions, antagonists appear to be
safe even when administered by chronic oral treatment. In reviewing the preclinical and
clinical data from the use of A2AR antagonists, and the acute and chronic effects of different
A2AR antagonists in rodent and non-human primate models of PD, their potential as non-
dopaminergic medication in the therapy of parkinsonian patients can be assessed.
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6.1. Reduction of motor symptoms by A2AR antagonists
The essential role of A2AR in modulating motor activity has been established in behavioural
studies employing selective ligands. Indeed, administration of the A2AR agonist CGS-21680
inhibits motor behaviour (Janusz & Berman, 1992; Barraco et al., 1993; Karcz-Kubicha et
al., 2003), whereas the A2AR antagonist SCH-58261 stimulates motor activity (10:
Svenningsson et al., 1997; Halldner et al., 2000; Lindskog et al., 2002). Consequently,
beneficial effects of A2AR blockade on motor deficits have been demonstrated in a number
of animal models of PD, including reversion of catalepsy induced by haloperidol or of
hypomotility by reserpine and modulation of turning behaviour in unilateral 6-OHDA-
lesioned rodents, as well as attenuation of motor impairment in MPTP-treated non-human
primates (Xu et al., 2005; Simola et al., 2008).
Several A2AR antagonists effectively counteract catalepsy in rodents, reducing its duration
and severity, thereby improving parkinsonian motor impairment (Kanda et al., 1994;
Shiozaki et al., 1999; Villanueva-Toledo, 2003; Pinna et al., 2005; Stasi et al., 2006;
Gillespie et al., 2009; Hodgson et al., 2009). Furthermore, the co-administration of L-DOPA
with A2AR antagonists such as KW-6002 (5), KF 17837 or ST-1535 (14) strengthens the
anticataleptic effect of the former, indicating the existence of a synergistic interaction
between L-DOPA and A2AR antagonists (Kanda et al., 1994; Shiozaki et al., 1999; Stasi et
al., 2006). As in the catalepsy model, acute administration of several A2AR antagonists to
unilateral 6-OHDA-lesioned rats significantly potentiates turning behaviour induced by L-
DOPA or apomorphine, and by D1R or D2R agonists (Vellucci et al., 1993; Pollack & Fink,
1996; Pinna et al., 1996, 2005, 2010; Fenu et al., 1997; Koga et al., 2000; Rose et al., 2007;
Tronci et al., 2007; Hodgson et al., 2009). In addition to turning behaviour, finer features of
PD symptoms resulting from neuron degeneration have been assessed in unilateral 6-
OHDA-lesioned rats, including forelimb akinesia, gait impairment and sensory-motor
integration deficits. These deficits are considered similar to PD-associated symptoms in
humans and have been measured in specific tests, such as initiation of stepping time,
adjusting step counting and vibrissae-elicited forelimb placing tests (Olsson et al., 1995;
Schallert et al., 2000). Like the L-DOPA effect, A2AR blockade reversed the impairment
observed in these tests, suggesting that in PD patients not afflicted by L-DOPA related side-
effects, A2AR antagonists may ameliorate diverse parkinsonian symptoms, even when
administered as a monotherapy (Pinna et al., 2007, 2010).
Other studies have indicated that A2AR antagonists exert beneficial effects in rat models of
parkinsonian rigidity and resting tremor, which can be as disabling as bradykinesia and
akinesia. The clinical muscular rigidity, characterized by increased resistance to passive
movement, can be mimicked in rodents with adequate doses of haloperidol or reserpine,
inducing muscle rigidity with mechanographic and electromyographic features similar to
those observed in PD patients (Lorenc-Koci et al., 1996). These effects are reversed by
A2AR blockade with SCH-58261 (10), (Wardas et al., 2001; Wardas, 2003). Moreover,
combined administration of SCH-58261 with L-DOPA, which alone has no effect on
haloperidol- or reserpine-induced muscle rigidity, induced pronounced synergistic effects
and marked alleviation of the symptoms (Wardas et al., 2001; Wardas, 2003). These
beneficial effects on parkinsonian-like muscular rigidity of A2AR antagonists are likely
mediated by the facilitation of postsynaptic dopamine transmission (Wardas et al., 2001;
Wardas, 2003).
The antitremorigenic effects of drugs can be evaluated in rodents by measuring their ability
to reverse tremulous jaw movements induced by several pharmacological agents, including
the cholinesterase inhibitor tacrine, the muscarinic agonist pilocarpine, haloperidol and the
neurotoxin 6-OHDA (Salamone et al., 1998). Acute administration of A2AR antagonists
significantly reversed jaw tremor stimulated by tacrine, haloperidol or pimozide in rats,
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suggesting these compounds may be useful to specifically combat this parkinsonian
symptom (Correa et al., 2004; Simola et al., 2004, 2006; Tronci et al., 2007; Salamone et al.,
2008; Pinna et al., 2010). Moreover, infusion of the A2AR antagonist SCH-BT2 in different
regions of striatum provided evidence that the ventrolateral but not the dorsolateral striatum
was critical to completely reverse tacrine-induced tremulous jaw movements (Simola et al.,
2004). On the basis of the critical role of increases in striatal acetylcholine in the genesis of
tremulous jaw movements (Salamone et al., 1998), modulation of cholinergic transmission
by A2AR antagonists may underlie the anti-tremorigenic effects of these drugs. Indeed, in
line with results obtained in rodents, acute administration of A2AR antagonists increased
locomotor activity in a dose-dependent manner and they reversed motor disabilities in non-
human primates previously rendered parkinsonian with the dopaminergic neurotoxin MPTP
(Kanda et al., 1998, 2000; Grondin et al., 1999; Rose et al., 2006; Hodgson et al., 2010).
Moreover, A2AR antagonists act synergistically with L-DOPA to restore motor deficits, as
well as with dopamine D1R and D2R agonists, in MPTP-treated non-human primates
(Kanda et al., 2000; Rose et al., 2006; Hodgson et al., 2010).
To summarize, findings obtained in animal models of PD strongly indicate that acute
administration of A2AR antagonists not only ameliorate motor impairment but also
effectively counteract parkinsonian-like muscle rigidity and resting tremor. Notably, these
latter effects are of particular interest for clinical application of A2AR antagonists since in
parkinsonian patients, muscle rigidity and resting tremor are often resistant to commonly
prescribed antiparkinsonian drugs. Moreover, synergistic interactions between L-DOPA and
A2AR antagonists have been described in different experimental models, suggesting that
they may be co-administered to potentiate the motor stimulant effects.
6.2. Reduction of dyskinesia by A2AR antagonists
As seen for acute administration, chronic administration of A2AR antagonists effectively
improves motor deficits in animal models of PD and does not produce tolerance to the motor
stimulant effects. By contrast, the non-specific adenosine antagonist caffeine loses its motor
stimulant effect after repeated administration (Fredholm et al., 1999; Halldner et al., 2000).
In unilateral 6-OHDA-lesioned rats, the potentiation of the intensity of L-DOPA-induced
turning behaviour elicited by acute SCH-58261 (10) administration can be observed even
after two weeks of repeated daily treatment with this A2AR antagonist (Pinna et al., 2001).
Similar results were reported following the combined administration of KF-17837 or
KW-6002 (5) and apomorphine, which specifically increased the duration rather than the
intensity of turning behaviour (Koga et al., 2000). In MPTP-treated common marmosets,
chronic treatment with KW-6002 (5) also attenuated parkinsonian motor disability with no
sign of tolerance (Kanda et al., 1998). Moreover, like the increased duration of
apomorphine-induced turning behaviour produced by acute treatment with A2AR
antagonists, co-administration of KW-6002 (5) and L-DOPA prevents the shortening of
turning behaviour induced by chronic L-DOPA, reflecting a possible benefit of A2AR
blockade on the L-DOPA-induced “wearing off” phenomenon observed in PD patients
(Koga et al., 2000; Oh & Chase, 2002; Bibbiani et al., 2003). However, this effect on
“wearing off” was not confirmed with the A2AR antagonist CSC (6), which appears to
reverse but not prevent the decrease in motor response duration induced by repeated L-
DOPA administration (Bové et al., 2002).
Interesting results have been obtained concerning the modulation of dyskinesia by A2AR
blockade when comparing the sensitization of turning behaviour and/or the development of
abnormal involuntary movements (AIMs) elicited by long-term treatment of a full dose of L-
DOPA (rodent models of dyskinesia) with an equipotent combination of a lower dose of L-
DOPA plus a A2AR antagonist (Pinna et al., 2001; Tronci et al., 2007; Hodgson et al., 2009).
While treatment with L-DOPA (high dose) and L-DOPA (lower dose) plus SCH-58261 (10),
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preladenant (12) or ST-1535 (14) produced a comparable degree of turns upon the first
administration, sensitization of turning behaviour and/or AIMs was observed in response to
chronic L-DOPA alone but not when administered with an A2AR antagonist (Pinna et al.,
2001; Tronci et al., 2007; Hodgson et al., 2009).
The stable response observed after long-term administration of L-DOPA with an A2AR
antagonist suggests that the association between the two drugs represents a treatment with
lower dyskinetic potential. Interestingly, this hypothesis was supported by studies showing
that genetic deletion of the A2AR prevents the sensitization of turning behaviour and AIMs
stimulated by L-DOPA in 6-OHDA-lesioned mice (Fredduzzi et al., 2002; Xiao et al.,
2006). Indeed, 6-OHDA-lesioned rats treated with KW-6002 (5) did not develop any AIMs
(Lundblad et al., 2003), while motor disabilities assessed with a rotarod test improved.
However, KW-6002 (5) did not prevent the severity of AIMs induced by L-DOPA in this
study when the two drugs were chronically co-administered and L-DOPA given at a full
dose. Hence, co-treatment with an A2AR antagonist and L-DOPA did not prevent the
development of AIMs if L-DOPA was given at a full dose to severely dopamine-denervated
rats (Lundblad et al., 2003).
The findings from rodent models of dyskinesia have been confirmed and expanded in
MPTP-treated marmoset and cynomolgus monkeys. Firstly, in MPTP-treated non-human
primates previously rendered dyskinetic by chronic L-DOPA, A2AR antagonists induced no
dyskinesia per se (Kanda et al., 1998; Grondin et al., 1999; Hodgson et al., 2010).
Furthermore, no sign of dyskinesia was observed in parkinsonian cynomolgus monkeys
chronically treated with apomorphine and KW-6002 (5: Bibbiani et al., 2003). In fact, in
dyskinetic MPTP-treated common marmosets the relief of motor impairment produced by an
optimal dose of L-DOPA, which presented a high dyskinetic potential, was similar to that of
the combination of KW-6002 (5) or preladenant (12) plus a suboptimal dose of L-DOPA,
which was associated with poor induction of dyskinesia (Kanda et al., 2000; Hodgson et al.,
2010). Interestingly, no exacerbation of dyskinetic movements was observed after brief
administration of KW-6002 (5) plus L-DOPA to dyskinetic MPTP-treated marmosets,
further supporting the potential of A2AR antagonists in palliating dyskinesia (Kanda et al.,
2000).
Taken together, data from preclinical studies indicates that chronic A2AR antagonist
administration has beneficial effects on PD motor impairment and on motor complications
produced by long-term L-DOPA treatment. These effects are of considerable interest given
that motor complications represent an intrinsic limitation of L-DOPA therapy that is often
insensitive to pharmacological manipulation. Moreover, since little tolerance to the motor
effects of A2AR antagonists is evident, these drugs may be used successfully over long
periods, rendering them particularly suitable for a prolonged pharmacological treatment such
as that required in PD.
7. Effects of A2AR antagonists in parkinsonian patients: results from clinical
trials
The development of new highly selective adenosine A2AR antagonists, and their
encouraging antiparkinsonian responses in animal models of PD, has provided a rationale
for clinical trials to evaluate the therapeutic potential and the safety of these agents in PD
patients.
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Although early clinical trials were prompted by several Pharmaceutical Companies, the vast
majority of data available on the effectiveness of A2AR antagonists in PD patients has been
collected using the xanthine derived compound istradefylline (also named KW-6002: 5)
produced by Kyowa Hakko Kyogo (Jenner, 2005).
In early phase IIa clinical trials with KW-6002 (at doses between 20-80 mg/day), patients
with moderate-to-severe PD and overt motor complications were evaluated using the motor
Unified PD Rating Scale (UPDRS motor: Bara-Jimenez et al., 2003; Hauser et al., 2003).
These studies demonstrated that when administered alone, KW-6002 (40 or 80 mg/day) has
no effect on either motor impairment or dyskinesia in PD patients (Bara-Jimenez et al.,
2003), whereas in conjunction with a low dose of L-DOPA (which alone has no
antiparkinsonian effect), KW-6002 (80 mg/day) significantly improves motor impairment to
a similar extent to an optimal dose of L-DOPA, while eliciting weaker dyskinetic effects.
Indeed, co-administration led to a beneficial effect on all cardinal symptoms in PD patients,
particularly on resting tremor (Bara-Jimenez et al., 2003). When co-administered with a
standard amount of L-DOPA, all doses of KW-6002 prolonged the half-life of the optimal
L-DOPA dose, indicating that KW-6002 reduced the time spent in the L-DOPA off state
(OFF Time: Bara-Jimenez et al., 2003; Hauser et al., 2003). Moreover, while the severity of
dyskinesia remained unchanged, the ON Time with dyskinesia increased following
KW-6002 administration (Bara-Jimenez et al., 2003; Hauser et al., 2003).
In two large phase IIb trials (US-005 and US-006) and a phase III (US-013) trial carried out
on advanced PD patients suffering “wearing-off” (with or without dyskinesia), treatment
with L-DOPA alone or in combination with other PD medications confirmed that KW-6002
(at all doses between 20-60 mg/day) produced a significant decrease in L-DOPA OFF Time
in PD patients (LeWitt et al., 2008; Stacy et al., 2008; Hauser et al., 2008). Importantly,
these studies included an essential measure to differentiate between “troublesome” and
“non-troublesome” dyskinesia during L-DOPA ON Time, demonstrating that KW-6002
significantly increased L-DOPA ON Time with non-troublesome dyskinesia, whereas L-
DOPA ON Time with troublesome dyskinesias remained unchanged (LeWitt et al., 2008;
Stacy et al., 2008; Hauser et al., 2008). Interestingly, a long phase III clinical study
(US-007) of PD patients who had previously been involved in other studies (US-001,
US-005 and US-006) showed that the efficacy of KW-6002 in reducing the OFF Time at
doses of between 20 and 60 mg/day was maintained in patients who were already taking the
drug at the onset of the study, providing evidence of consistent and sustained effects (Factor
et al., 2010). Similar efficacy of KW-6002 was confirmed in a Japanese phase III study
(6002-0608) in which the OFF Time was not only significantly reduced at doses of 20 and
40 mg/day but also, UPDRS motor scores were seen to improve (Mizuno et al., 2010).
Notably, KW-6002 (40 mg/day) was recently assessed as a monotherapy in early PD
patients (US-051 trial: Fernandez et al., 2010); albeit the improvement was not statistically
significant across groups, UPDRS motor scores were better at all time points (and
significantly better at week two) (Fernandez et al., 2010). The inability of KW-6002
monotherapy to reverse parkinsonian disability in humans contrasts with findings in animal
models of PD (Kanda et al., 1998, 2000; Grondin et al., 1999; Shiozaki et al., 1999; Pinna et
al., 2007). This discrepancy may be explained by the low doses used in clinical trials. Higher
doses of KW-6002 may be required when administered alone to elicit beneficial effects upon
parkinsonian symptoms.
Some safety concerns were raised following observations in A2AR knockout mice of
increased blood pressure, as well as irritability and anxiety. However, in all clinical trials
KW-6002 has appeared to be well tolerated and safe. No notable differences were detected
in systolic/diastolic blood pressure, heart rate or respiration rate in patients treated with
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KW-6002 (Hauser et al., 2003), and although anxiety was reported by a small percentage of
patients (3 out of 54) treated with the antagonist, the effect was not dose-dependent and only
one such case received the highest dose (Hauser et al., 2003). Similarly, the irritability
typically observed in A2AR KO mice was not reported by any patient treated with KW-6002
(Bara-Jimenez et al., 2003; Hauser et al., 2003; LeWitt et al., 2008; Stacy et al., 2008;
Hauser et al., 2008; Mizuno et al., 2010). The most common adverse effects (AEs) appear to
be nausea, aggravation of dyskinesia, dizziness and insomnia, although discontinuation due
to AEs was no more frequent than in placebo groups (Bara-Jimenez et al., 2003; Hauser et
al., 2003, 2008; LeWitt et al., 2008; Stacy et al., 2008; Factor et al., 2010). Although the
clinical effects obtained with KW-6002 are not always statistically significant, they clearly
indicate that doses of 20-80 mg/day of this drug reduce the OFF Time by 0.7–1.2 h in PD
patients. The drug leads to an increase in ON Time with dyskinesia, though most of this
increase can be attributed to non-troublesome dyskinesia. Nevertheless, KW-6002 did not
receive the approval by the Food and Drug Administration (FDA) in 2008 despite the
positive findings, with the agency expressing concerns as to whether the results from clinical
trials supported the clinical utility for KW-6002 and demanding more thorough clinical
investigations (www.istradefylline.com/fda.html). Considering the positive clinical results
obtained in PD patients, Kyowa decided to perform a further thorough study to elucidate the
full potential of KW-6002 as a treatment for PD. Importantly, in PD patients this drug has
yet to be tested under similar circumstances to those which revealed positive effects in
rodent and primate studies. For example, KW-6002 may be co-administered with a sub-
optimal dose of dopamine agonists or L-DOPA, instead of with the optimal doses used so
far in clinical trials.
Besides KW-6002, a number of other A2AR antagonists have also entered clinical trials.
Accordingly, we will summarize the data recently made available for: preladenant
(SCH-420814, 12 from Merck & Co Inc. following its acquisition of Schering-Plough
Corp); SYN-115 (15: from Roche-Synosia Therapeutics); vipadenant (BIIB014/V2006, 13:
from Vernalis plc-Biogen Idec); and ST-1535 (14: from Sigma-Tau. Pinna, 2009; Shah &
Hodgson, 2010). Other companies are also working in this field (Adenosine Therapeutics,
Palo Biofarma, Neurocrine Biosciences, Almirall Prodesfarma, and Lundbeck) but have yet
to disclose significant information related to specific drug development programmes (Pinna,
2009; Shah & Hodgson, 2010).
7.2. Preladenant
Preladenant (previously known as SCH-420814: 12) is a non-xanthine adenosine A2AR
antagonist currently under development for PD treatment by Merck & Co Inc. (following its
acquisition of Schering-Plough Corp). It was derived from the well-known SCH-58261 (10),
a pharmacological tool widely used to characterize the A2AR subtype (Neustadt et al., 2007).
Preladenant has good oral bioavailability, it is very selective for A2AR with good
pharmacokinetic (PK) properties, and it has excellent in vivo activity against parkinsonian
symptoms (Neustadt et al., 2007; Hodgson et al., 2009).
A phase I positron emission tomography (PET) trial in healthy humans using the
[11C]SCH-442416 (11) radiotracer has been undertaken to correlate plasma concentration of
preladenant (after 10, 50 and 200 mg) and neural-mediated effects. Accordingly, receptor
occupancy in the human brain was maximal at low concentrations of preladenant and the
duration occupancy was dose-dependent (Brooks et al., 2009), which supports the possibility
of developing preladenant under a twice daily (BID) administration regime. In parallel, the
efficacy of the molecule was initially investigated in two phase IIa studies that employed
short-term administration of this compound (BID, dosing over 1-3 days), concomitant to L-
DOPA, and measuring motor function with the UPDRS motor score. These phase IIa studies
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demonstrated that short-term treatment with preladenant plus L-DOPA produced an
improvement in motor function in PD patients (Hunter, 2006).
A more extensive international phase II clinical trial (P04501) on preladenant as adjunctive
therapy evaluated the efficacy and safety of four different doses (1, 2, 5 or 10 mg BID, 12
weeks) in patients with moderate-to-severe PD that experienced dyskinesia and motor
fluctuations (Hauser et al., 2011). All patients were on a stable regime of standard treatments
with L-DOPA and other adjunctive medications, such as dopamine agonists and/or
entacapone. At doses of 5 and 10 mg BID, preladenant was significantly more effective in
reducing the OFF Time than the placebo. In addition, at both doses preladenant significantly
increased the ON Time without producing a proportional overall increase in troublesome or
non-troublesome dyskinesia, (Hauser et al., 2011).
A further phase II trial (P05175), a 36 week extension to the P04501 trial, was undertaken to
assess the long-term safety of preladenant at a dose of 5 mg BID administered in
combination with L-DOPA or dopamine agonists (Pinna, 2009; Shah & Hodgson, 2010).
The results of this phase II trial in moderate-to-severe PD patients who participated in the
main study (P04501) have not yet been disseminated. In addition, a phase II trial (P06402)
to administer preladenant (2, 5 or 10 mg BID, 12 weeks) in combination with L-DOPA in
Japanese patients with moderate-to-severe PD is currently at the recruitment stage
(www.clinicaltrials.gov/ct2/results?term=preladenant). Moreover, four phase III trials
(P05664, P04938, P07037 and P06153) with preladenant (2, 5 and 10 mg BID) are
underway to evaluate its efficacy in early PD patients as monotherapy over 52 weeks
(www.clinicaltrials.gov/ct2/results?term=P05664) in moderate-to-severe PD patients, as
adjunctive therapy for 12 weeks
(www.clinicaltrials.gov/ct2/results?term=P04938;www.clinicaltrials.gov/ct2/results?
term=P07037) and, a 40 week extension of the P04938 and P07037 studies
(www.clinicaltrials.gov/ct2/results?term=P06153). From the information available to date
from trials, preladenant has been demonstrated to be safe and well tolerated at all doses, with
a similar incidence of AEs and discontinuation rates between groups that received
preladenant or the placebo (Hauser et al., 2011). A small increase in systolic and diastolic
blood pressure was initially observed in patients administered preladenant groups, but this
returned to baseline values when measured from 2 to 12 weeks after beginning the treatment
(Hauser et al., 2011). Indeed, no dose-dependent effect on blood pressure was detected upon
visual inspection of the data. The most frequently AEs reported were worsening PD,
dyskinesia and somnolence, which arose at approximately the same frequency in
preladenant and placebo groups. There was no clinically significant drug effect on pulse,
respiration, or other laboratory and ECG parameters (Hauser et al., 2011).
7.3. SYN-115
Another promising, potent and selective non-xanthine A2AR antagonist is SYN-115 (15),
which is under development to treat PD by Synosia Therapeutics (acquired in February 2011
by Biotie Therapies) and UCB Pharma. SYN-115 was originally developed by Roche and
licensed to Synosia in 2007
(www.biotie.com/en/recearch_and_development/central_nervous_system_disorders/
syn115). On the basis of very promising results obtained in preclinical studies, the company
decided to perform a phase IIa study with SYN-115 in patients with mild-to-moderate PD.
In this study, administration of oral SYN-115 (20 or 60 mg BID, one week), alone or in
combination with an infusion of low dose of L-DOPA, was evaluated using a number of
techniques, including functional magnetic resonance imaging (fMRI, a tool to rapidly
evaluate the pharmacodynamic effects of drugs in the brain), and clinical ratings such as the
UPDRS motor scores and tapping speed (Black et al., 2010a, 2010b). SYN-115 produced a
dose-responsive decrease in cerebral blood flow in regions of the brain known to be
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sensitive to drugs used to treat PD (Black et al., 2010a). Moreover, at 60 mg BID this
compound significantly improved tapping speed, both with and without a sub-therapeutic
infusion of L-DOPA (Black et al., 2010b). Compared to the placebo, total UPDRS motor
scores fell by 20% with SYN-115 when administered with L-DOPA (Black et al., 2010b).
Moreover, when considered individually, 10 of 13 items were better with SYN-115 than
with placebo; in particular, there were significant improvement in two UPDRS measures of
bradykinesia (finger tapping and rapidly alternating hand movements: Black et al., 2010b).
These effects were less efficacious at a dose of 20 mg. SYN-115 was well tolerated at both
doses and no serious AEs occurred (Black et al., 2010b). On the basis of these promising
results, Biotie and UCB are planning to start a phase IIb study over a 12-week treatment
period to evaluate the effects of four doses of SYN-115 versus placebo as a L-DOPA




The non-xanthine compound vipadenant (13), previously known as BIIB014/V2006, was
synthesized by Vernalis plc, who have an agreement with Biogen Idec to develop and
commercialise the drug. On the basis of its pharmacological and PK profile, vipadenant was
selected for clinical antiparkinsonian evaluation (Gillespie et al., 2009) and indeed, this
compound has a high affinity and good selectively for A2AR, as well as good oral
bioavailability, a long plasma half-life and good brain penetration (Gillespie et al., 2009).
These preclinical PK results have been confirmed in healthy humans, showing that
vipadenant is appropriate for further development as a single daily treatment (He et al.,
2010). Moreover, a PET receptor occupancy study in humans demonstrated that vipadenat is
delivered to the brain and that A2AR occupancy is related to both dose and plasma levels
(Brooks et al., 2010).
The pharmacological efficacy and safety of vipadenant as an antiparkinsonian drug were
investigated in two clinical phase II trials. In the first phase II trial, oral administration of
vipadenant (daily, 8 weeks) showed dose-dependent efficacy as an adjunct therapy in
association with the habitual L-DOPA treatment of patients with moderate-to-severe PD
displaying motor fluctuations; the treatment increased the total ON Time without
troublesome dyskinesia and decreasing the OFF Time (Papapetropoulos et al., 2010a). The
second phase II study evaluated the effect of vipadenant as monotherapy in patients with
early-stage PD (Pinna, 2009), demonstrating that this compound produces a clinically
relevant decrease in UPDRS motor scores in a dose-dependent manner (Pinna, 2009).
Moreover, Biogen Idec reported that vipadenant was well tolerated in phase II clinical trials
in which there was a low incidence of AEs in vipadenant-treated PD patients
(Papapetropoulos et al., 2010b). Despite these promising results in phase II clinical studies,
development of vipadenant was discontinued in June 2010
(www.vernalis.com/media-centre/latest-releases/2010-releases/584), based on a review of
preclinical toxicology findings. As an alternative approach, the two companies are
advancing preclinical studies of V81444 to file a phase I clinical trial in 2011. V81444 is
considered by the pharmaceutical company as a “next-generation compound” designed to
address the chemical structural liability that may have led to the concerns regarding the
toxicity of vipadenant (www.vernalis.com/media-centre/latest-releases/596).
7.5. ST-1535
ST-1535 (14) was developed by Sigma-Tau with the aim of generating new non-xanthine
A2AR antagonists on the basis of A2AR ligand structure-function information (Minetti et al.,
2005). After several preclinical studies in rodent and non-human primate models of PD, in
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which ST-1535 displayed clear efficacy as an antiparkinsonian drug (Pinna, 2009), a phase I
clinical study was designed to ascertain the safety and tolerability of the compound, as well
as the most convenient dose. All single doses of ST-1535 (50, 100, 200, 300 and 450 mg)
were generally well tolerated and no haematological, biochemical or urinary laboratory
abnormalities noted. Based on results of this ongoing phase I clinical study
(www.sigma-tau.it/eng/areediricerca.asp), an evaluation of the safety and PK profile of
ST-1535 at multiple doses (50, 100, 150 and 200 mg/day, two weeks) has been planned.
Moreover, the company has started to investigate the antiparkinsonian activity of two
metabolites of ST-1535, ST-3932 and ST-4206, which have good efficacy in rodent models
of PD (Vertecchi et al., 2010).
7.6 Future directions
The positive clinical effects displayed by these A2AR antagonists strongly supports the
introduction of anti-A2AR medications in the management of parkinsonian patients. Indeed,
the observed reduction of L-DOPA OFF Time is of particular interest, since “wearing off”
(progressive shortening of L-DOPA motor effects) is one of the major disadvantages of
long-term use of this drug. Nevertheless, further studies are required to improve
management with A2AR antagonists, particularly in combination with a sub-optimal dose of
L-DOPA, as suggested by preclinical trials. Additional results from patients with early stage
of PD are expected to elucidate whether A2AR antagonists are suitable for administration as
monotherapy against motor symptoms. Finally, evaluation of these drugs in patients devoid
of L-DOPA motor complications should be performed in order to assess in more detail the
effect of A2AR antagonists on the onset and progress of human dyskinesia.
8. Rationale for developing safer and more effective antiparkinsonian drugs
based on targeting A2AR heteromers
8.1. Targeting striatal pre- or postsynaptic A2ARs
The powerful capacity of presynaptic A2ARs to modulate striatal glutamate release was first
demonstrated through in vivo microdialysis experiments (Popoli et al., 1995), which
revealed that striatal perfusion of an A2AR agonist produced a very pronounced increase in
the basal concentrations of extracellular striatal glutamate. Similarly, intra-striatal perfusion
of an A2AR antagonist through a microdialysis probe significantly counteracted striatal
glutamate release induced by cortical electrical stimulation in the orofacial premotor cortex
(Quiroz et al., 2009). Strikingly, an unexpected finding was that this counteracting of
glutamate release was accompanied by a complete impairment of the jaw movements
induced by the cortical electrical stimulation, demonstrating the crucial role of presynaptic
A2ARs in the control of cortico-striatal glutamatergic neurotransmission. By combining
cortical electrical stimulation and recording of EMG activity of the mastication muscles, a
Power Correlation Coefficient (PCC) can be used as a quantitative in vivo measure of
cortico-striatal neurotransmission (Quiroz et al., 2009). PCC was shown to be significantly
diminished by systemic administration of an A2AR receptor antagonist in a dose dependent
manner. Therefore, the PCC could be used to screen the presynaptic effect of A2AR
antagonists.
A recent surprising yet fundamental finding is that several A2AR antagonists previously
considered to be pharmacologically similar in fact present different striatal pre- and
postsynaptic profiles (Orrú et al., 2011). Six compounds already known as selective A2AR
antagonists were first screened for their ability to block striatal pre- and postsynaptic A2ARs
in in vivo models. Locomotor activation was used to evaluate postsynaptic activity while
counteracting the PCC was used to determine presynaptic activity (see above). SCH-442416
(11) and KW-6002 (5) preferentially acted pre- and postsynaptically, respectively, and four
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compounds had mixed pre-postsynaptic profiles: MSX-3 (7a), preladenant (12), SCH-58261
(10) and ZM-241385 (9). The combination of in vivo microdialysis with cortical electrical
stimulation was used as an additional means to evaluate presynaptic activity of A2AR
antagonists in vivo. In agreement with its preferential presynaptic profile, SCH-442416 (11)
counteracted striatal glutamate release induced by cortical stimulation at a dose that strongly
counteracted the PCC but did not induce locomotor activation. In accordance with its
preferential postsynaptic profile, KW-6002 (5) did not modify striatal glutamate release
induced by cortical stimulation at a dose that produced pronounced locomotor activation but
did not counteract PCC.
Importantly, at least some of the pharmacological differences between A2AR antagonists
may be explained by the ability of pre- and postsynaptic A2ARs to form different receptor
heteromers with A1Rs and D2Rs, respectively (Orrú et al., 2011). Differences in the affinity
of these compounds for different A2AR heteromers were assessed in cells stably expressing
A2ARs, A2AR-D2R heteromers or A1R-A2AR heteromers by radioligand-binding. Co-
expression with A1R did not significantly modify the affinity of A2AR for the different
ligands, although co-expression with D2R decreased the affinity of all compounds, with the
exception of KW-6002 (5: Orrú et al., 2011). The structural changes in A2AR induced by
heteromerization with D2R were not only detected by antagonists but also by agonist
binding. Indeed, the affinity of the selective A2AR agonist CGS-21680 was reduced in cells
co-transfected with D2Rs. In attempting to explain the differential effects of SCH-442416
(11) observed in vivo, it is interesting to note that this compound in particular exhibited a
much higher affinity for the A2AR in a presynaptic versus postsynaptic-like context. In fact,
the affinity of A2AR for SCH-442416 (11) in cells expressing A2AR-D2R heteromers was
markedly reduced (40-fold higher B50 values in competitive-inhibition experiments with
[3H]ZM-241385 in cells expressing A2AR-D2R than A1R-A2AR heteromers).
The decrease in affinity upon co-expression with D2R was much less pronounced for
ZM-241385, SCH-58261 (10), MSX2 (7) or preladenant, for which the affinity fell 2-9 fold
(Orrú et al., 2011). Considering that these A2AR antagonists behaved qualitatively similar to
the A2AR agonist CGS-21680 in terms of binding to A1R-A2AR and A2AR-D2R heteromers,
it was expected that these four compounds would compete equally for the binding of the
endogenous agonist at pre- and at postsynaptic sites. This would fit with the in vivo data,
which showed that these compounds do not prefer pre-postsynaptic profiles. However,
KW-6002 (5) was the only antagonist whose affinity was not significantly different in cells
expressing A2AR, A1R-A2AR heteromers or A2AR-D2R heteromers. Thus, KW-6002 (5)
exhibited the best relative affinity for A2AR-D2R heteromers of all compounds, which may
partially explain its preferential postsynaptic profile. Experiments performed with the non-
selective adenosine receptor antagonist caffeine also revealed a good correlation between the
in vivo data and the in vitro preference for postsynaptic A2AR-containing heteromers. In
transfected mammalian cells, the affinity of A2AR for the non-selective adenosine receptor
antagonist caffeine did not change when co-transfected with D2R, although it was
significantly decreased (about 10 times) when co-transfected with A1R (Ciruela et al., 2006).
As predicted, caffeine did not significantly reduce PCC at doses that produce pronounced
motor activation (Zanoveli et al., in the press).
8.2. A2AR heteromers as targets for drug development
The results described above support the proposal that receptor heteromers may be used as
selective targets for drug development, particularly given the very specific neuronal
localization of receptor heteromers (even more specific than the receptor subtypes
themselves) and the distinct ligand affinity of a receptor depending on its partner (or
partners) in the heteromer. Striatal A2AR-containing heteromers are particularly interesting
targets, and especially relevant for a variety of neuropsychiatric disorders. Blocking
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postsynaptic A2ARs in the enkephalinergic MSNs may be beneficial for PD, as this strategy
should decrease the activity of the indirect striatal efferent pathway. Potentiating the effect
of L-DOPA or other dopamine receptor agonists on D2R-mediated signalling in the A2AR-
D2R heteromer would exert beneficial effects. However, it should be noted that blockade of
presynaptic A2ARs (that form heteromers with A1Rs or not) in glutamatergic terminals
contacting dynorphinergic MSNs will decrease glutamatergic transmission through the
direct striatal efferent pathway, thereby diminishing motor activity and consequently, the
antiparkinsonian efficacy of A2AR antagonists. The most convenient A2AR antagonist to
treat Parkinson’s disease patients should ideally exhibit a higher affinity for post-synaptic
versus pre-synaptic receptors. However, selective blockade of presynaptic A2AR is likely to
be useful in dyskinetic disorders such as HD, as well as in obsessive-compulsive disorders
and drug addiction. It should also be possible to explore whether “pre-synaptic” A2AR
antagonists effectively ameliorate L-DOPA-induced dyskinesia.
The antiparkinsonian activity of KW-6002 (5) can be explained mechanistically by
heteromer–related findings (Orrú et al., 2011), suggesting that SCH-442416 (11) may be
useful in the treatment of dyskinetic disorders, obsessive-compulsive disorders and drug
addiction. Medicinal chemistry and in silico modelling should help elucidate the molecular
properties that determine the particular pharmacological profile of SCH-442416 (11) and
KW-6002 (5), which may serve as lead compounds to develop more effective antidyskinetic
and antiparkinsonian compounds, respectively.
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Abbreviations
AR adenosine receptor(s)
A2AR adenosine A2A receptor(s)
AD Alzheimer’s disease
AE adverse effects
AIMs abnormal involuntary movements
Akt protein kinase B
BBB Blood brain barrier
CB1R cannabinoid CB1 receptor(s)
CNS central nervous system
DA dopamine
COX cyclooxygenase
D1R dopamine D1 receptor(s)
D2R dopamine D2 receptor(s)
L-DOPA L-3,4-dihydroxyphenylalanine
eGFP enhanced green fluorescent protein
FDA Food and Drug Administration
GABA gamma-amino butyric acid
GDNF glial-derived neurotrophic factor






MAPK mitogen-activated protein kinase
mGlu5R metabotropic glutamate receptor, subtype number 5
MPP+ 1-methyl-4-phenylpyridinium
MSN medium spiny neurons
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NECA 5’-N-ethylcarboxamidoadenosine
NGF nerve growth factor
NMDA N-methyl-D-aspartate
6-OHDA 6-hydroxydopamine
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PCC Power correlation coefficient
PD Parkinson’s disease
PET Positron emission tomography
SNc substantia nigra pars compacta
SNr substantia nigra pars reticolata
STN subthalamic nucleus
TNF tumor necrosis factor
UPDRS motor motor unified PD rating scale
UPS ubiquitin/proteasomal system
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Figure 1. A2A adenosine receptor antagonists: xanthine derivatives
A major metabolite of caffeine in humans, paraxanthine (3) is an A2AR antagonist as potent
as caffeine that contributes to the in vivo activity of caffeine (Arnaud, 2011). A synthetic
analogue of caffeine, 3,7-dimethyl-1-propargylxanthine (DMPX, 4) exhibits a somewhat
higher affinity for the A2A versus the A1 receptor, and has thus been used in vitro and in
vivo as the first “A2A-selective” AR antagonist (Seale et al., 1988). However, DMPX is only
very moderately selective with respect to A1 and it is not selective for the A2B receptor (see
Table 1). Truly A2AR-selective xanthine derivatives include the 8-styrylxanthine derivatives
istradefylline (KW6002, 5: Kase, 2003), 8-(m-chlorostyryl) caffeine (CSC, 6: Jacobson et
al., 1993), and MSX-2 (7: Sauer et al., 2000; Hockemeyer et al., 2004). In contrast to the 8-
unsubstituted xanthine derivatives (1-4), which exhibit acceptable to good water-solubility,
the 8-styrylxanthines (5-7) are relatively insoluble in water. Therefore, water soluble
prodrugs of MSX-2 have been developed, such as the phosphate prodrug MSX-3 (7a:
Hockemeyer et al., 2004) and the L-valine ester prodrug MSX-4 (7b: Vollmann et al., 2008),
which represent very valuable pharmacological tools, particularly for in vivo studies (e.g.,
Randall et al., 2011; Collins et al., 2010; Mott et al., 2009; Bilkei-Gorzo et al., 2008;
Schindler et al., 2005; Blum et al., 2003; Hauber et al., 1998). These drugs are very water-
soluble but readily cleaved by enzymatic hydrolysis. Both compounds can be applied by
injection, but are also bioavailable after peroral administration (unpublished results). CSC
(5) acts as a dual compound, inhibiting monoamine oxidase B (MAO-B) and blocking the
A2AR to a similar extent (Ki A2A: 54 nM, Ki MAO-B: 80.6 nM). By contrast, istradefylline
(5) and MSX-2 (7) do not inhibit MAO-B, or only at concentrations that are >100-fold
higher than those required for A2A receptor blockade (see Table 1). Istradefylline is the only
A2AR -selective xanthine derivative being evaluated in clinical trials (see Figure 2).
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Figure 2. A2AR antagonists: non-xanthine derivatives
Several classes of non-xanthine A2AR antagonists have been developed (see Figure 2 and
Table 1). The antagonists frequently used in pharmacological experiments include the non-
selective CGS-15943 (8), and the A2AR -selective compounds ZM-241385 (9) and
SCH-58261 (10). All of these amino-substituted heterobi- or –tricyclic compounds are
structurally related to adenosine, although they lack the ribose sugar moiety (see Figure 2).
The X-ray structure of the A2AR protein complexed with antagonist 9 has been obtained,
revealing the binding site for antagonists (Jaakola et al., 2008). Very recently an agonist-
bound X-ray structure of the A2AR was published showing that the agonist, an adenosine
derivative, occupies virtually the same binding site as antagonist 9 (Xu et al., 2011). A
further optimized compound derived from SCH-58261 (10) has been generated,
SCH-442416 (11), which exhibits improved selectivity and is used in a 11C-labelled form as
a tracer for positron emission tomography (PET: see below). Another analogue of 10 is
preladenant (12), which is currently being evaluated in clinical trials for the treatment of PD
(see below: Salamone, 2010). Two additional aminopurine or aminoazapurine derivatives
that have been tested in clinical trials are vipadenant (BII014, V2006, 13 : Gillespie et al.,
2009) and ST-1535 (14: Stasi et al., 2006). While preladenant is highly A2AR -selective, the
latter compounds (13 and 14) are less selective (see Table 1). The first selective A2AR
antagonist to be tested clinically that is not structurally related to xanthine or adenine was
the benzothiazole derivative SYN-115 (15: Black et al., 2010). Compound 15 also shows
high selectivity for the A2AR.
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